Ception Increases Series C

Ception Therapeutics Inc., a Malvern, Pa.-based drug company whose lead candidates are anti-inflammatories, has raised $14.7 million in additional Series C funding from existing shareholders Third Point and Greenlight Capital. This brings the Series C round total to $77 million, following an initial close that included participation from Essex Woodlands Health Ventures, Investor Growth Capital, MDS Life Sciences, New Science Ventures and Aperture Venture Partners. http://www.ceptiontx.com/